Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC
Status:
Completed
Trial end date:
2020-10-27
Target enrollment:
Participant gender:
Summary
This is an international, open-label, non-controlled, multicenter phase II clinical trial
with two different primary objectives: a biological and a clinical objective.
From a clinical point of view, the objective is to assess the clinical benefit of the
combination of palbociclib and hormonotherapy in patients with advance breast cancer that had
previously received endocrine therapy in combination with palbociclib and had achieved
clinical benefit during palbociclib treatment with subsequent disease progression.
From a biological point of view, the challenge is to define a molecular profile that allow
identifying patients that could benefit more from continuing on palbociclib after progression
on a prior palbociclib-containing regimen